The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.In a statement, Health ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

Lenacapavir, which was approved by the United States' Food and Drug Administration in June this year, is taken twice per year ...